Katrina Church - Bioventus VP Officer
| BVS Stock | USD 11.50 0.21 1.79% |
Insider
Katrina Church is VP Officer of Bioventus
| Age | 62 |
| Address | 4721 Emperor Boulevard, Durham, NC, United States, 27703 |
| Phone | 919 474 6700 |
| Web | https://www.bioventus.com |
Katrina Church Latest Insider Activity
Tracking and analyzing the buying and selling activities of Katrina Church against Bioventus stock is an integral part of due diligence when investing in Bioventus. Katrina Church insider activity provides valuable insight into whether Bioventus is net buyers or sellers over its current business cycle. Note, Bioventus insiders must abide by specific rules, including filing SEC forms every time they buy or sell Bioventus'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Katrina Church over three months ago Disposition of 2559 shares by Katrina Church of Bioventus at 5.57 subject to Rule 16b-3 | ||
Katrina Church over three months ago Disposition of 8600 shares by Katrina Church of Bioventus subject to Rule 16b-3 | ||
Katrina Church over three months ago Disposition of 26875 shares by Katrina Church of Bioventus subject to Rule 16b-3 | ||
Katrina Church over six months ago Disposition of 1325 shares by Katrina Church of Bioventus at 4.75 subject to Rule 16b-3 |
Bioventus Management Efficiency
The company has Return on Asset of 0.0248 % which means that on every $100 spent on assets, it made $0.0248 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2476) %, meaning that it generated no profit with money invested by stockholders. Bioventus' management efficiency ratios could be used to measure how well Bioventus manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.46 in 2024. Return On Capital Employed is likely to gain to -0.12 in 2024. At this time, Bioventus' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 3.3 M in 2024, whereas Total Current Assets are likely to drop slightly above 212 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Laurent Duhoux | Nuwellis | N/A | |
| M Harrison | NanoVibronix | N/A | |
| Veronica Cai | Tivic Health Systems | 48 | |
| Shunichi Kuroda | Bone Biologics Corp | N/A | |
| Bradford Amman | Vivos Therapeutics | 62 | |
| Mark Feinberg | Bluejay Diagnostics | N/A | |
| Jonathan Paris | Rapid Micro Biosystems | 48 | |
| Blake Gurfein | Tivic Health Systems | 40 | |
| RaeAnn Byrnes | Vivos Therapeutics | N/A | |
| Danielle Watson | Heart Test Laboratories | 42 | |
| John Wilson | Rapid Micro Biosystems | 56 | |
| Rob Scott | Nuwellis | N/A | |
| Jason Cook | Bluejay Diagnostics | 42 | |
| Mark MD | Bluejay Diagnostics | N/A | |
| Victoria Vezina | Rapid Micro Biosystems | 56 | |
| Harold MD | NanoVibronix | 70 | |
| Sanjay Ahuja | Tivic Health Systems | N/A | |
| Julie Gannon | Vivos Therapeutics | N/A | |
| Kevin Vance | Bluejay Diagnostics | 66 | |
| William MD | Nuwellis | N/A | |
| CPA CPA | NanoVibronix | 68 | |
Management Performance
| Return On Equity | -0.25 | ||||
| Return On Asset | 0.0248 |
Bioventus Leadership Team
Elected by the shareholders, the Bioventus' board of directors comprises two types of representatives: Bioventus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bioventus. The board's role is to monitor Bioventus' management team and ensure that shareholders' interests are well served. Bioventus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bioventus' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kenneth Reali, CEO Director | ||
| MBA BS, Senior Operations | ||
| Mark Singleton, Senior CFO | ||
| Helen Leupold, Senior Officer | ||
| Katrina Church, VP Officer | ||
| Alessandraa Pavesio, VP Officer | ||
| Anthony JD, General VP | ||
| Larry Chen, Managing Pacific | ||
| Anthony James, VP Quality | ||
| Anthony DAdamio, General VP | ||
| Robert Claypoole, CEO President | ||
| David Crawford, Vice Treasurer | ||
| Miguel BeltranDelgado, VP Operations | ||
| Katrina JD, Senior Officer | ||
| Jeff Welch, VP Devel | ||
| Christopher Yamamoto, Sr Strategy |
Bioventus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bioventus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.25 | ||||
| Return On Asset | 0.0248 | ||||
| Profit Margin | (0.07) % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 1.09 B | ||||
| Shares Outstanding | 65.37 M | ||||
| Shares Owned By Insiders | 11.47 % | ||||
| Shares Owned By Institutions | 69.76 % | ||||
| Number Of Shares Shorted | 1.34 M | ||||
| Price To Earning | 6.96 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Bioventus Stock Analysis
When running Bioventus' price analysis, check to measure Bioventus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioventus is operating at the current time. Most of Bioventus' value examination focuses on studying past and present price action to predict the probability of Bioventus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioventus' price. Additionally, you may evaluate how the addition of Bioventus to your portfolios can decrease your overall portfolio volatility.